Nektar Therapeutics Cash Flow - Quarterly (NASDAQ:NKTR)

Add to My Stocks
$22.89 $1.06 (4.86%) NKTR stock closing price Mar 22, 2017 (Closing)

The financial analysis of NKTR requires an investor to check the cash flows for Nektar Therapeutics. Financials statements like the income statement and balance sheet show that the company has Nektar Therapeutics profits and Nektar Therapeutics debt, while the cash flow statement provides details of cash flow movments. Nektar Therapeutics had cash and cash equivalents of $55.57M at beginning of quarter and $59.64M at quarter end for 2016-Q4. Nektar Therapeutics cash flow analysis tells whether or not the company has enough cash for its day to day activities, and for investing for future growth. Nektar Therapeutics had an outflow of $52.41M from operating activities, $190.96M inflow due to financing activities, and $142.1M spend due to investing activities for 2016-Q4. View details of Nektar Therapeutics cash flows for latest & last 40 quarters.

show more
View Previous Quarters
View Next Quarters
Fiscal year is Jan - Dec. 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3
Nektar Therapeutics Net Income Cash Flow
Depreciation Depletion Amortization Cash-Flow15.35M11.5M7.63M3.71M12.85M9.1M5.83M2.97M12.92M9.73M
Net Increase (Decrease) in Assets Liabilities7.93M26.01M16.47M-12.12M-34.7M6.23M18.44M21.19M-116.42M-60.81M
Cash From (used in) Discontinued Operations----------
Other Adjustments Net13.22M9.19M6.74M4.25M29.94M13.72M10.61M5.32M15.4M-58.06M
Nektar Therapeutics Net Cash from (used by) Operating Activities
Increase (Decrease) in Prop Plant And Equipment-6.39M-3.74M-3.23M-1.67M-11.19M-8.72M-4.58M-1.05M-9.97M-6.09M
Acquisition Disposition of Subsidiaires----------
Increase (Decrease) in Investments-76.01M63.44M34.55M37.92M-28.14M-23.4M-8.25M54.21M-27.59M-6.67M
Other Cash Inflow (Outflow) from Investment Activities----25M25M----
Nektar Therapeutics Net Cash from (used by) Invesment Activities
Issuance (Purchase) of Equity Shares209.56M18.04M9.64M6.09M32.2M15.51M7.79M1.68M163.52M132.7M
Issuance (Repayment) of Debt Securities-5.95M-5.37M-3.51M-1.72M98.57M-3.79M-2.48M-1.09M-3.53M-2.57M
Increase (Decrease) in Bank & Other Borrowings----------
Payment of Dividends & Other Cash Distributions----------
Other Cash from (used by) Financing Activities---------7M-7M
Nektar Therapeutics Net Cash from (used by) Financing Activities
Effect of Exchange Rate Changes on Cash-0.12M-0.03M-0.09M0.01M-0.15M-0.15M-0.02M0.03M-0.1M-0.04M
Nektar Therapeutics Net Change in Cash & Cash Equivalents
Cash & Equivalents at Beginning of Year55.57M12.36M39.06M25.43M15.31M17.75M49.59M155.58M76.29M63.76M
Cash & Equivalents at Year End59.64M63.29M55.67M72.54M55.57M18.81M20.87M129.45M12.36M32M
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters
Get Cash flow for another ticker

While Nektar Therapeutics stock price history provides the price history of a stock, Nektar Therapeutics stock comparison chart shows the same in comparison to peers, and cash flow statements provide cash position of the company. Common terms used in the statement of cash flows are:
  • Nektar Therapeutics saw a decrease in Net Change in Cash and Cash Equivalents from $7.72M in 2016-Q3 to $4.07M in 2016-Q4. Apart from the Nektar Therapeutics stock price, this is one of the things an investor looks for, as it shows the net change in cash on hand for a company, compared to previous period.
  • Cash Flow from operating activities: Nektar Therapeutics reported a negative operating cash flow of $-117.02M for 2016-Q4 and has seen a decrease from the previous quarter. Operating cash flow or working capital comes from main business activities. Investors look for positive cash flow from recurring operating activities.
  • Growth companies (typically most tech companies) spend heavily  on investing activities and this figure was negative at $-82.4M for NKTR stock. Sometimes a company might have a negative overall cash flow which may not be really bad if it is due to investment expenses. Hence it is important to check the cash flow from investment activities.
  • Cash Flow from financing activities: The cash inflow/outflow from financing activities was $203.62M for Nektar Therapeutics. The money accounted for under this head comes from external sources which includes lenders, investors and shareholders. Positive cash flow is generated when the company gets cash because of issuance of stocks or bonds. Similarly negative cash flow is generated when shares are repurchased, dividend payments are made, and loans or interest on loans are paid back.

Key Financial Ratios For Nektar Therapeutics Cash Flow

FCF margin